Drugs / NEI-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05226468 | Apr 2022 → Jan 2024 | acute myeloid leukemia | New Epsilon Innovation Limited | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEI-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05226468 ↗ |
| Route | Intravenous | “Intravenous single dose of NEI-01 with 4 ascending dose levels.” NCT05226468 ↗ |